<DOC>
	<DOCNO>NCT02171000</DOCNO>
	<brief_summary>To investigate safety , pharmacokinetics pharmacodynamics BIBR 1048 MS follow oral administration multiple dos ( 150 mg b.i.d. , 7 day )</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics After Multiple Oral Doses BIBR 1048 MS Capsule Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Healthy male subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate body temperature ) , 12lead ECG , clinical laboratory test 1.1 No find clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥20 Age ≤35 year 3 . Body Mass Index ( BMI ) ≥18 BMI &lt; 25 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission trial accordance Japanese GCP ( Ministry Health , Labour Welfare Ordinance No.28 , March 27 , 1997 ) . 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Subject able use adequate form contraception time first dose Day 1 endof study examination 3 . Diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder 4 . History clinically significant orthostatic hypotension , clinically significant current past fainting spell blackout . 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant safety assessment judge investigator ( exclude asymptomatic seasonal rhinitis/hay fever ) bleed disorder include prolonged habitual bleeding hematologic diseases cerebral bleeding ( e.g . car accident ) concussion ( head trauma result injure brain ) without loss consciousness 7 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives , whichever short , respective drug prior administration trial 8 . Use aspirin ( include overthecounter medication ) , antiplatelet agent like ticlopidine dipyridamole , chronic administration nonsteroidal antiinflammatory drug ( NSAIDs , coumadin like anticoagulant , chronic use corticosteroid , heparin fibrinolytic agent within 14 day prior administration endofstudy examination 9 . Participation another trial investigational drug within 3 month prior administration endofstudy examination 10 . Smoker ( &gt; 10 cigarettes/day inability refrain smoke trial ) 11 . Alcohol abuse ( 60 g/day ; confirm interview ) 12 . Drug abuse ( confirm interview ) 13 . Blood donation ( 100 mL 3 month prior screen blood donation screen endofstudy examination ) 14 . Excessive physical activity ( within 7 day prior first drug administration endofstudy examination ) 15 . Any laboratory value outside reference range clinical relevance 16 . Known hypersensitivity investigational drug excipients 17 . Subject judge ineligible investigator subinvestigator 18 . History familial bleeding disorder 19 . Thrombocytes &lt; 15 x 104 /μL</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>